Abstract
This study analyzed the relationship between four renin–angiotensin system (RAS) gene polymorphisms and the response to blood pressure lowering and development of microalbuminuria in 206 patients with essential hypertension treated once daily for 12 months with telmisartan 80 mg. Seated cuff blood pressure and urinary albumin excretion (UAE) were measured throughout the study. Patients were screened for the presence of the A-6G variant of the angiotensinogen gene, angiotensin-converting enzyme insertion/deletion polymorphism, and the A1166C and C573T polymorphisms of the angiotensin II type 1 receptor gene. No significant association was found between the presence of any gene polymorphism and the reduction of blood or UAE following telmisartan treatment. The results indicate that these RAS gene polymorphisms do not affect the antihypertensive activity and renoprotection in mild-to-moderate hypertensive patients treated with telmisartan.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921.
Materson BJ, Reda DJ, Cushman WC . Department of Veterans Affairs Single-Drug Therapy of Hypertension Study. Revised figures and new data. Am J Hypertens 1995; 8: 189–192.
Edmonds D, Huss R, Jeck T, Mengden T, Schubert M, Vetter W . Individualizing antihypertensive therapy with enalapril vs atenolol: the Zurich experience. J Hypertens 1990; 8(Suppl 4): S49–S52.
The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991; 151: 1413–1423.
Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 1053–1060.
Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E . Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001; 19: 1–11.
Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC et al. Age–race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 1998; 280: 1168–1172.
Hall J . Historical perspective of the renin–angiotensin system. Mol Biotechnol 2003; 24: 27–39.
Chaves FJ, Pascual JM, Rovira E, Armengod ME, Redón J . Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens 2001; 14: 364–370.
Chaves FJ, Giner V, Corella D, Pascual J, Marin P, Armengod ME et al. Body weight changes and the A-6G polymorphism of the angiotensinogen gene. Int J Obes Relat Metab Disord 2002; 26: 1173–1178.
Redón J, Chaves FJ, Liao Y, Pascual JM, Rovira E, Armengod ME et al. Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension. Hypertension 2000; 35: 490–495.
Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P . Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin–angiotensin system genes. J Hypertens 1996; 14: 259–262.
Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T . Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11: 174–183.
Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783–1787.
Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvanen AC et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999; 33: 844–889.
Hilgers KF, Langenfeld MR, Schlaich M, Veelken R, Schmieder RE . 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation 1999; 100: 1394–1399.
Miller JA, Thai K, Scholey JW . Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56: 2173–2180.
Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW . Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000; 36: 411–416.
Giner V, Corella D, Chaves FJ, Pascual JM, Portoles O, Marin P et al. Renin–angiotensin system genetic polymorphisms and essential hypertension in the Spanish population. Med Clin (Barc) 2001; 117: 525–529.
Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocates study. J Hypertens 2003; 21: 81–86.
Fatini C, Abbate R, Pepe G, Battaglini B, Gensini F, Ruggiano G et al. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J 2000; 21: 633–638.
Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Csaszar A . Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. Clin Chim Acta 1998; 269: 91–100.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630–635.
Tilzer L, Thomas S, Moreno RF . Use of silica gel polymer for DNA extraction with organic solvents. Anal Biochem 1989; 183: 13–15.
Rigat B, Hubert C, Corvol P, Soubrier F . PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20: 1433.
Wang WY, Glenn CL, Zhang W, Benjafield AV, Nyholt DR, Morris BJ . Exclusion of angiotensinogen gene in molecular basis of human hypertension: sibpair linkage and association analyses in Australian anglo-caucasians. Am J Med Genet 1999; 87: 53–60.
Acknowledgements
The study was supported by a Research Grant of Glaxo, Spain.
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix A1
Appendix A1
List of researchers of the POLPRI study J Redon, V Giner, Hospital Clínico Universitario, Valencia; M Luque, N Martel, Hospital Clinico San Carlos, Madrid; C Fernandez-Torres, Hospital Virgen de las Nieves, Granada; S Najaty, Hospital Clínico Universitario, Valladolid; J Olivan, Hospital Virgen de la Macarena, Sevilla; A Martin-Hidalgo, Hospital General Universitario, Elche; P Cia, Hospital Clínico Universitario, Zaragoza; MA Courel, Hospital Xeral, Vigo; J Plana, Hospital San Camil, Barcelona; J Villatoro, Hospital General, Castellon; C Fernandez, Ciudad Sanitaria Virgen del Rocio, Sevilla; J Poblador, Hospital General, Mallorca; P Aranda, Hospital Regional Carlos Haya, Málaga; J Abellan, Centro de Salud, Murcia; J Viladoms, Hospital de Mollet de Vallés, Barcelona; A Martinez-Amenos, Hospital Principes de España, Hospitalet del Llobregat; A Liebana, Hospital Ciudad de Jaén, Jaen; A Salcedo, Hospital de Galdácano, Bilbao.
Rights and permissions
About this article
Cite this article
Redon, J., Luque-Otero, M., Martell, N. et al. Renin–angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 5, 14–20 (2005). https://doi.org/10.1038/sj.tpj.6500280
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500280
Keywords
This article is cited by
-
Telmisartan: clinical evidence across the cardiovascular and renal disease continuum
Drugs & Therapy Perspectives (2017)
-
Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System
Current Hypertension Reports (2011)
-
Renin–Angiotensin System and α-Adducin Gene Polymorphisms and Their Relation to Responses to Antihypertensive Drugs: Results From the GENRES Study
American Journal of Hypertension (2009)
-
Differential Roles of Angiotensinogen and Angiotensin Receptor type 1 Polymorphisms in Breast Cancer Risk
Breast Cancer Research and Treatment (2007)